Lobbyist Public Search

Records prior to registration year 2005 are not available online. Contact the Lobbyist Division here for assistance.	Search data is collected from registration records and disclosure reports submitted by lobbyists, lobbying entities, and their clients. Massachusetts General Law requires any party providing or retaining lobbying services to register annually, and submit disclosure reports twice a year.
	Your comments are welcome: submit feedback

Disclosure reporting details

Back to search detail summary

Lobbyist disclosure reporting period: 07/01/2021 - 12/31/2021

Lobbyist name	Geoffrey Gallo
Business name	AstraZeneca Pharmaceuticals LP
Address	701 Pennsylvania Avenue NW Suite 500
City, state, zip code	Washington, DC 20004
Country	US
Agent type	Both
Phone	603-772-1559

Operating Expenses

No operating expenses were filed for this disclosure reporting period.

Activities, Bill Numbers and Titles

Client: AstraZeneca Pharmaceuticals LP

Total amount paid by client; lobbyist is unable to report compensation at activity level: $29,500.00

House / Senate	Bill Number or Agency Name	Bill title or activity	Agent position	Amount	Direct business association
House Bill	1311	An Act relative to step therapy and patient safety	Support	$0.00	NA
Senate Bill	1915	An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing	Oppose	$0.00	NA
House Bill	1191	An Act to help patients and reduce health care costs by ensuring patient adherence to medications	Support	$0.00	NA
Senate Bill	1480	An Act to prevent undue influence on prescriber behavior	Oppose	$0.00	NA
Senate Bill	756	An Act relative to step therapy and patient safety	Support	$0.00	NA
House Bill	4269	The 5-year extension on the sunset for the Massachusetts Drug Take Back program via the American Rescue Plan Act funding bill	Neutral	$0.00	NA
House Bill	1137	An Act relative to cancer patient access to biomarker testing to provide appropriate therapy	Support	$0.00	NA
House Bill	2377	An Act to permit the wholesale importation of prescription drugs into the Commonwealth	Oppose	$0.00	NA
House Bill	4000	An Act making appropriations for the fiscal year 2022 for the maintenance of the departments, boards, commissions, institutions and certain activities of the Commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements	Oppose	$0.00	NA
House Bill	1175	An Act relative to the diagnosis and treatment of breast cancer	Neutral	$0.00	NA
House Bill	1053	An Act relative to consumer deductibles	Support	$0.00	NA
House Bill	1254	An Act relative to promoting comprehensive transparency in the pharmaceutical industry	Oppose	$0.00	NA
Senate Bill	697	An Act relative to insurance coverage for mammograms and breast cancer screening	Neutral	$0.00	NA
House Bill	1224	An Act relative to promoting healthcare access and affordability for patients	Support	$0.00	NA
Senate Bill	790	An Act to define modest meals and refreshments in prescriber education settings	Oppose	$0.00	NA
House Bill	0	Promoted and assisted with information pertaining to the Health Policy Commission study on the use of prescription drug coupons and vouchers. Interactions (virtual) with the Health Policy Commission and participation in the Health Policy Commission Advisory Council quarterly meetings (virtually). Participate in public meetings/discussions pertaining to drug costs (net and gross) and value-based contracts with health plans as well as Medicaid and the Children's Health Insurance Program. Promoted the overall clinical value of prescription medicines and the economic impact of the biotechnology sector in the Commonwealth of Massachusetts.	Support	$0.00	NA
House Bill	729	An Act to ensure prescription drug cost transparency and affordability	Oppose	$0.00	NA
House Bill	1279	An Act establishing a commission to review contracts between pharmaceutical benefit managers and MassHealth	Neutral	$0.00	NA
House Bill	0	Engaged in discussions with members of the Executive and Legislative branches concerning the development and potential rollout of AstraZeneca’s COVID-19 vaccine and AstraZeneca’s monoclonal antibody Evusheld. As of the filing of this report, AstraZeneca’s vaccine has yet to be approved by the Food & Drug Administration. Thus, these discussions were for planning purposes only in the event the vaccine was approved. The discussions on Evusheld were in response to distribution via the federal government after receiving emergency use authorization from the Food & Drug Administration. Specifically on COVID-19 vaccine, members of the Legislative House COVID-19 Working Group. These topics pertained to the progress of clinical trials, distribution, and supply. Engaged on various COVID-19 current Executive Orders to ensure compliance with our essential workers in Massachusetts to include the updated winter advisory dated 21 Dec 2021.	Neutral	$0.00	NA
House Bill	1210	An Act relative to drug prices paid by carriers	Oppose	$0.00	NA
House Bill	4253	An Act Enhancing the Market Review Process	Neutral	$0.00	NA
Senate Bill	808	An Act relative to cancer patient access to biomarker testing to provide appropriate therapy	Support	$0.00	NA
Senate Bill	785	An Act to improve the accessibility and affordability of pharmaceutical drugs of public health concern	Oppose	$0.00	NA
Senate Bill	696	An Act to help patients and reduce healthcare costs by ensuring patient adherence to medications	Support	$0.00	NA
Senate Bill	1481	An Act to restore integrity in the marketing of pharmaceutical products and medical devices	Oppose	$0.00	NA
Senate Bill	627	An Act relative to promoting healthcare access and affordability for patients	Support	$0.00	NA
Senate Bill	804	An Act to promote transparency and prevent price gouging of pharmaceutical drug prices	Oppose	$0.00	NA
House Bill	0	Engaged in the Health Policy Commission Drug Pricing Review Process to include public comment and the Standard Reporting Form. Specifically the process for determining valuation of Rx drugs, transparency reporting requirements and rebate negotiations. Member of the Health Policy Commission Advisory Council and participated virtually on their quarterly meetings.	Oppose	$0.00	NA
Senate Bill	771	An Act relative to pharmaceutical access, costs and transparency	Oppose	$0.00	NA
House Bill	1247	An Act to ensure more affordable care	Neutral	$0.00	NA
Senate Bill	644	An Act relative to consumer deductibles	Support	$0.00	NA
House Bill	1278	An Act relative to prescription drug price transparency	Oppose	$0.00	NA
Senate Bill	728	An Act relative to pharmaceutical gag clauses	Neutral	$0.00	NA
House Bill	1201	An Act ensuring access to medications	Support	$0.00	NA
Senate Bill	786	An Act to bring down the cost of prescription drugs	Oppose	$0.00	NA
House Bill	1237	An Act relative to non-medical switching	Support	$0.00	NA
Senate Bill	1456	An Act to define clinical social work practice	Oppose	$0.00	NA
			Total amount	$0.00

Meals, Travel, and Entertainment Expenses

No meals, travel, or entertainment expenses were filed for this disclosure reporting period.

Additional Expenses

No additional expenses were filed for this disclosure reporting period.

Campaign Contributions

Date	Recipient name	Office sought	Amount
09/09/2021	Brad Jones	State Representative	$200.00
09/09/2021	Jeff Roy	State Representative	$200.00
09/28/2021	Nick Collins	State Senate	$200.00
09/30/2021	Akriti Bhambi	Cambridge School District Committee	$200.00
10/12/2021	Danielle Gregoire	State Representative	$200.00
10/15/2021	Karyn Polito	Lieutenant Governor	$200.00
10/26/2021	Rob Consalvo	State Representative	$200.00
11/08/2021	Dan Ryan	State Representative	$200.00
11/08/2021	Bill Driscoll	State Representative	$200.00
11/15/2021	Denise Garlick	State Representative	$200.00
11/16/2021	Democratic Senate Committee	Democratic Senate Committee	$200.00
11/19/2021	Lydia Edward	State Senate	$100.00
12/09/2021	Alice Peisch	State Representative	$100.00
		Total contributions	$2,400.00

Close this page

Connect with Us